Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.03 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enriched outside the brain (cdc) | 0.10 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 3 Parkinson's papers of 1,795 | 0.82 |
| pathways Reactome | 2 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 6673
Sealed predictions
- CCL17 in dopamine neurons, braak-0.36 (p 0.342) → -0.43 (p 0.244)receipt 6680
Swarm cases
receipt 6680: CCL17 in dopamine neurons, braak
- power
- full sample -0.39 (p 0.111, n 18), 95% CI -0.72 to +0.10. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.40 (p 0.097, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.51 (p 0.032, n 18). not the mix.
- skeptic
- leave-one-out range -0.54 to -0.31, sign flips 0; without severely affected donors -0.39 (p 0.111, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CCL17 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts